Enanta Pharmaceuticals, Inc. (ENTA) Analysts See $0.09 EPS; Profile of 3 Analysts Covering Falcon Oil & Gas Ltd. (LON:FOG)

April 17, 2018 - By Lawrence Diaz

Analysts expect Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to report $0.09 EPS on May, 14.They anticipate $0.37 EPS change or 132.14% from last quarter’s $-0.28 EPS. ENTA’s profit would be $1.72M giving it 248.61 P/E if the $0.09 EPS is correct. After having $0.78 EPS previously, Enanta Pharmaceuticals, Inc.’s analysts see -88.46% EPS growth. The stock increased 4.13% or $3.55 during the last trading session, reaching $89.5. About 90,075 shares traded. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has risen 160.80% since April 17, 2017 and is uptrending. It has outperformed by 149.25% the S&P500.

Among 4 analysts covering Falcon Oil Gas (LON:FOG), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Falcon Oil Gas had 23 analyst reports since August 27, 2015 according to SRatingsIntel. The rating was maintained by Cantor Fitzgerald on Tuesday, September 8 with “Buy”. The stock of Falcon Oil & Gas Ltd. (LON:FOG) has “Buy” rating given on Thursday, December 3 by FinnCap. The rating was maintained by FinnCap on Thursday, April 21 with “Buy”. Cantor Fitzgerald maintained the shares of FOG in report on Thursday, May 26 with “Buy” rating. FinnCap maintained it with “Buy” rating and GBX 23 target in Wednesday, July 5 report. The company was maintained on Thursday, December 3 by Cantor Fitzgerald. As per Tuesday, September 1, the company rating was maintained by Cantor Fitzgerald. The stock has “Buy” rating by FinnCap on Friday, February 17. The firm has “Speculative Buy” rating given on Thursday, November 19 by Beaufort Securities. The company was maintained on Tuesday, January 26 by FinnCap. See Falcon Oil & Gas Ltd. (LON:FOG) latest ratings:

14/12/2017 Broker: RBC Capital Markets Rating: Sector Performer New Target: GBX 25.00 Initiates Starts
10/11/2017 Broker: FinnCap Rating: Buy Old Target: GBX 23.00 New Target: GBX 23.00 Maintain

The stock increased 2.13% or GBX 0.5 during the last trading session, reaching GBX 24. About 4.83M shares traded or 664.98% up from the average. Falcon Oil & Gas Ltd. (LON:FOG) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Falcon Oil & Gas Ltd., an oil and gas company, engages in the acquisition, exploration, and development of unconventional and conventional gas and oil assets in Australia, Hungary, South Africa, and Canada. The company has market cap of 216.02 million GBP. It holds interests in 3 exploration permits covering an area of approximately 1.4 million net acres in the Beetaloo Basin, Northern Territory, Australia. It currently has negative earnings. The firm also has a technical cooperation permit covering an area of approximately 7.5 million acres in the southwest Karoo Basin, South Africa; and production license covering an area of approximately 245,775 acres in the Makó Trough located in south-eastern Hungary.

Investors sentiment decreased to 1.58 in 2017 Q4. Its down 0.02, from 1.6 in 2017Q3. It worsened, as 12 investors sold Enanta Pharmaceuticals, Inc. shares while 36 reduced holdings. 29 funds opened positions while 47 raised stakes. 13.64 million shares or 12.66% more from 12.10 million shares in 2017Q3 were reported. Aqr Mngmt Ltd Co holds 0.01% or 155,182 shares in its portfolio. Dekabank Deutsche Girozentrale holds 4,600 shares. Gsa Cap Prtnrs Ltd Liability Partnership holds 0.03% or 9,400 shares. Louisiana State Employees Retirement Sys has 0.02% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Dupont Cap has 0.01% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Virginia Retirement Systems Et Al holds 0.01% or 21,100 shares in its portfolio. Granahan Inv Mgmt Ma holds 89,811 shares. Northern owns 200,357 shares. Principal Grp Incorporated Inc accumulated 109,959 shares or 0.01% of the stock. Jpmorgan Chase Com invested in 0% or 166,287 shares. Strs Ohio has 16,800 shares for 0% of their portfolio. Jacobs Levy Equity Mgmt Inc, New Jersey-based fund reported 29,400 shares. Envestnet Asset Mngmt has invested 0% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Lazard Asset Ltd Com accumulated 0% or 12,068 shares. Matarin Capital Mngmt Limited Liability Corp reported 286,957 shares.

Since March 19, 2018, it had 0 insider buys, and 1 sale for $778,331 activity. $778,331 worth of stock was sold by MELLETT PAUL J on Monday, March 19.

Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company has market cap of $1.72 billion. The company??s research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus. It has a 51.11 P/E ratio. It has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>